OP25: Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trialsYear: 2022
Source: ECCO'22
Authors: Ferrante, M.(1);Cao, Q.(2);Fujii, T.(3);Rausch, A.(4);Neimark, E.(5);Song, A.(6);Wallace, K.(6);Kligys, K.(7);Zhou, Q.(8);Kalabic, J.(9);Feagan, B.G.(10);
Created: Friday, 11 February 2022, 3:52 PM
OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative dataYear: 2023
Source: ECCO’23 Copenhagen
Authors: Van Linschoten, R.(1,2,3)*;van Leeuwen, N.(2);Hazelzet, J.A.(2);van der Woude, C.J.(3);van Noord, D.(4);West, R.L.(4);
Created: Friday, 14 July 2023, 10:43 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s diseaseYear: 2019
Source: ECCO '19 Copenhagen
Authors: E. Dreesen*1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D’Haens13, S. Vermeire14,15, A. Gils1
Created: Friday, 22 February 2019, 9:41 AM
OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitisYear: 2020
Authors: M. Iacucci1, S.C. Smith2, A. Bazarova2, U.N. Shivaji1, P. Bhandari3, R. Cannatelli2, M. Daperno4, J.G. Ferraz5, M. Goetz6, X. Gui7, B. Hayee8, G. De Hertogh9, M. Lazarev10, J. Li11, O.M. Nardone2, V. Occhipinti12, R. Panaccione5, A. Parra-Blanco13, L. Pastorelli12, T. Rath14, G. Tontini15, M. Vieth16, V. Villanacci17, D. Zardo18, R. Kiesslich19, R. Bisschops20, S. Ghosh1
Created: Thursday, 30 January 2020, 10:12 AM
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 studyYear: 2022
Source: ECCO'22
Authors: D'Haens, G.(1);Kobayashi, T.(2);Morris, N.(3);Lissoos, T.(3);Hoover, A.(3);Li, X.(3);Arora, V.(3);Milch, C.(3);Sandborn, W.J.(4);Sands, B.E.(5);
Created: Friday, 11 February 2022, 3:52 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trialYear: 2023
Source: ECCO’23 Copenhagen
Authors: Aguas Peris, M.(1,2)*;Del Hoyo, J.(1,2);Vicente, R.(3,4);Barreiro-de Acosta, M.(5);Melcarne, L.(6);Hernández-Camba, A.(7);Alfambra, E.(8,9);Madero, L.(10,11);Sicilia, B.(12);Chaparro, M.(13,14,15,16);Martín-Arranz, M.D.(14,17,18);Pajares, R.(19);Mesonero, F.(20);Mañosa, M.(16,21);Martínez, P.(22);Chacón , S.(23);Tosca, J.(24);Marín, S.(25,26);Sanromán, L.(27,28,29,30);Calvo, M.(31);Monfort, D.(32);Saiz, E.(33);Zabana, Y.(16,34);Guerra, I.(35);Varela, P.(36);Faubel, R.(37,38,39);Corsino, P.(3,4);Porto-Silva, S.(5);Brunet, E.(6);Gutiérrez, A.(10,11,16);Nos, P.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS studyYear: 2019
Source: ECCO '19 Copenhagen
Authors: S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11
Created: Friday, 22 February 2019, 9:41 AM
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studiesYear: 2021
Source: ECCO'21 Virtual
Authors: Schreiber , S.W.(1);Ferrante , M.(2);Panaccione , R.(3);Colombel , J.F.(4);Hisamatsu , T.(5);Lim , A.(6);Lindsay , J.O.(7);Rubin , D.T.(8);Sandborn , W.J.(9);Neimark , E.(10);Song , A.P.(10);Liao , X.(10);Feng , T.(10);Berg , S.(10);Wallace , K.(10);D’Haens , G.R.(11)
Created: Wednesday, 2 June 2021, 4:12 PM
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension studyYear: 2020
Authors: M. Ferrante1, B.G. Feagan2, J. Panés3, F. Baert4, E. Louis5, O. Dewit6, A. Kaser7, W.R. Duan8, D. Gustafson9, X. Liao10, K. Wallace9, J. Kalabic11, G.R. D’Haens12
Created: Thursday, 30 January 2020, 10:12 AM
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy VolunteersYear: 2022
Source: ECCO'22
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCUYear: 2023
Source: ECCO’23 Copenhagen
Authors: Rubín De Célix, C.(1)*;Martín de Carpi, J.(2);Pujol, G.(2);Palomino, L.(3);Velasco, M.(3);Martín-Masot, R.(4);Navas-López, V.M.(4);Ricart, E.(5);Casanova, M.J.(1);Rodríguez Martínez, A.(6);Leo, E.(7);Alcaraz, A.(8);Mañosa, M.(9);Hernández, V.(10);Fernández, R.(10);Sánchez, C.(11);Menchén, L.(12);Mesonero, F.(13);Barreiro-De Acosta, M.(14);Martinon, N.(15);Tejido Sandoval, C.(16);Rendo Vázquez, A.(17);Corsino, P.(18);Vicente, R.(18);Hernández-Camba, A.(19);Alberto Alonso, J.R.(20);Alonso-Abreu, I.(21);Castro Millán, A.M.(22);Peries Reverter, L.(23);Castro, B.(24);Fernández-Salgado, E.(25);Busto Cuiñas, M.M.(26);Benítez, J.M.(27);Madero, L.(28);Clemente, F.(29);Riestra, S.(30);Jiménez-Treviño, S.(31);Boscá, M.(32);Chaparro, M.(1);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP27: Has been withdrawnYear: 2021
Source: ECCO'21 Virtual
Authors: Has been withdrawn
Created: Wednesday, 2 June 2021, 4:12 PM
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel diseaseYear: 2019
Source: ECCO '19 Copenhagen
Authors: V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1
Created: Friday, 22 February 2019, 9:41 AM
OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scoresYear: 2020
Authors: B. Steere1, K. GOTTLIEB1, J. Schmitz2, R. Higgs1, B. Jia1, C. Milch1, J. Tuttle3, V. Krishnan1, R. Belin1, W. Reinisch4
Created: Thursday, 30 January 2020, 10:12 AM
OP28: A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)Year: 2022
Source: ECCO'22
Authors: Truyens, M.(1,2,3);Lobaton, T.(1,3);Peeters, A.(1);Ferrante, M.(4,5);Vermeire, S.(4,5);Bossuyt, P.(6);Pouillon, L.(6);Dewint, P.(7,8);Cremer, A.(9);Peeters, H.(10);Lambrecht, G.(11);Louis, E.(12);Rahier, J.F.(13);Dewit, O.(14);Muls, V.(15);Holvoet, T.(1,16);Vandermeulen, L.(17);Gonzales, G.B.(2,3,18);Laukens, D.(2,3);De Vos, M.(3);
Created: Friday, 11 February 2022, 3:52 PM
OP28: The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 studyYear: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Sandborn, W.J.(2);Feagan, B.G.(3);Weisel, K.(4);Gonzalez, S.(4);Frustaci, M.E.(4);Yang, Z.(4);Johanns, J.(4);Germinaro, M.(4);Afzali, A.(5);Andrews, J.M.(6);D’Haens, G.(7);Hisamatsu, T.(8);Panaccione, R.(9);Reinisch, W.(10);Rubin, D.T.(11);Sands, B.E.(12);Panes, J.(13)
Created: Wednesday, 2 June 2021, 4:12 PM
OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida RegistryYear: 2020
Authors: M. Chaparro1, A. Garre1, F. Mesonero2, C. Rodríguez3, M. Barreiro-de Acosta4, J. Martínez-Cadilla5, M.T. Arroyo6, N. Manceñido7, M. Sierra-Ausín8, I. Vera-Mendoza9, M.J. Casanova1, P. Nos10, C. González-Muñoza11, T. Martínez12, M. Boscá-Watts13, D. Busquets14, M. Calafat15, E. Girona16, J. Llaó17, M.D. Martín-Arranz18, M. Piqueras19, L. Ramos20, G. Suis21, F. Bermejo22, A.Y. Carbajo23, D. Casas-Deza24, A. Fernández-Clotet25, M.J. García26, D. Ginard27, A. Gutiérrez-Casbas28, L. Hernández-Villalba29, A.J. Lucendo30, L. Márquez31, O. Merino-Ochoa32, F.J. Rancel33, C. Taxonera34, A. López Sanromán2, S. Rubio3, E. Domènech15, J.P. Gisbert1
Created: Thursday, 30 January 2020, 10:12 AM
OP29: Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiomeYear: 2021
Source: ECCO'21 Virtual
Authors: Bolte, L.(1,2);Vich Vila, A.(1,2);Imhann, F.(1,2);Collij, V.(1,2);Peters, V.(1);Fu, J.(2,3);Kurilshikov, A.(2);Campmans-Kuijpers, M.(1);Dijkstra, G.(1);Wijmenga, C.(2);Zhernakova, A.(2);Weersma, R.(1)
Created: Wednesday, 2 June 2021, 4:12 PM